Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- Find out if the study drugs Afatinib and Dasatinib can be safely given together to
patients with lung cancer
- Learn how these two drugs work in cancer cells when they are combined
- Learn more about the side effects of these two drugs when combined
- Find the highest doses of the study drugs Afatinib and Dasatinib that can be given
safely without causing serious side effects
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute